

August 31, 2020

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : **531099**
Sub : **Outcome of Board Meeting**

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held on Monday, August 31, 2020, inter alia, has considered and approved the following:

Unaudited Standalone Financial Results for the quarter ended June 30, 2020 along with the limited review report thereon;

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Rubra Medicaments Limited**



Abha Kapoor
Director (Finance) and CFO
DIN – 02799429

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2020

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for the previous year ended
		30-Jun-2020	31-Mar-2020	30-Jun-2019	31-Mar-2020
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	0.00	63.00	9.26	98.76
II	Other Income	0.00	0.00	0.00	0.00
III	Total Income (I + II)	-	63.00	9.26	98.76
IV	Expenses:				
	Cost of Materials Consumed	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	0.00	0.00	0.00	14.68
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00
	Employee benefits Expense	0.60	1.83	6.55	13.06
	Finance Costs	0.00	0.00	0.09	0.12
	Depreciation & amortisation expense	0.00	0.04	0.05	0.17
	Other Expenses	0.00	63.33	1.42	69.16
	Total Expenses (IV)	0.60	65.20	8.11	97.19
V	Profit / (loss) before exceptional items and tax (III-IV)	-0.60	-2.20	1.15	1.57
VI	Exceptional Items	0.00	3.06	0.00	3.06
VII	Profit / (loss) before tax (V-VI)	-0.60	0.86	1.15	4.63
VIII	Tax Expense:				
	(1) Current tax	0.00	1.45	0.00	1.45
	(2) Deferred tax	0.00	0.03	0.00	0.03
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-0.60	-0.62	1.15	3.15
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	-0.60	-0.62	1.15	3.15
XIV	Other comprehensive income				
	A (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss				
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-0.60	-0.62	1.15	3.15
XVI	Earnings per equity share (for continuing operation):				
	(1) Basic	0.00	0.00	0.02	0.06
	(2) Diluted	0.00	0.00	0.02	0.06
XVII	Earnings per equity share (for discontinued operation):				
	(1) Basic				
	(2) Diluted	0.00	0.00	0.00	0.06
XVIII	Earnings per equity share (for discontinued & continuing operation):				
	(1) Basic	0.00	0.00	0.02	0.06
	(2) Diluted	0.00	0.00	0.02	0.06
	NOTES:				
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.				
2	The Segment - wise details are not applicable to the Company as the Company has no segments.				
3	The results are Ind-AS compliant however, the previous year figures are not subject to limit review or audit. However the management has exercised necessary due - diligence to ensure that the Financial Results provide a true and fair view of its affairs.				
4	The result is provisional and unaudited and subject to change, regrouping and restatement.				

For Rubra Medicaments Limited



Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

Place: Mumbai
Date:- August 31, 2020

DD & COMPANY

CHARTERED ACCOUNTANT

**The Limited Review Report for listed entities other than banks and insurance companies -
unaudited standalone quarterly and year to date results**

To,
The Board of Directors
Rubra Medicaments Limited
Mumbai

We have reviewed the accompanying statement of unaudited financial results of Rubra Medicaments Limited for the period ended June 30, 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, M/s. DD & Company (FRN: 129273W)



C. A. Dinesh Agarwal (MRN: 045393)

Partner

UDIN:20045393AAAAAK5415

Place: Mumbai
Date: August 31, 2020